An ambulance arrives with U.S. doctor Kent Brantly, right, at Emory University Hospital, in Atlanta, on Saturday, Aug. 2, 2014. Brantly was flown from Liberia to Atlanta on Aug. 2, and is receiving treatment for Ebola at Emory University Hospital. (WSB-TV Atlanta/AP)
An ambulance arrives with U.S. doctor Kent Brantly, right, at Emory University Hospital, in Atlanta, on Saturday, Aug. 2, 2014. Brantly was flown from Liberia to Atlanta on Aug. 2, and is receiving treatment for Ebola at Emory University Hospital. (WSB-TV Atlanta/AP)
An ambulance arrives with U.S. doctor Kent Brantly, right, at Emory University Hospital, in Atlanta, on Saturday, Aug. 2, 2014. Brantly was flown from Liberia to Atlanta on Aug. 2, and is receiving treatment for Ebola at Emory University Hospital. (WSB-TV Atlanta/AP)

(Bloomberg) – A tiny San Diego-based company provided an experimental Ebola treatment for two Americans infected with the deadly virus in Liberia. The biotechnology drug, produced with tobacco plants, appears to be working.

In an unusual twist of expedited drug access, Mapp Biopharmaceutical Inc., which has nine employees, released its experimental ZMapp drug, until now only tested on infected animals, for the two health workers. Kentucky BioProcessing LLC, a subsidiary of tobacco giant Reynolds American Inc. (RAI:US), manufactures the treatment for Mapp from tobacco plants.

The first patient, Kent Brantly, a doctor, was flown from Liberia to Atlanta on Aug. 2, and is receiving treatment at Emory University Hospital. Nancy Writebol, an aid worker, is scheduled to arrive in Atlanta today and will be treated at the same hospital, according to the charity group she works with. Both are improving, according to relatives and supporters.

Each patient received at least one dose of ZMapp in Liberia before coming to the U.S., according to Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.

READ MORE

Leave a comment

Your email address will not be published.

Yes, I would like to receive emails from Washington Informer Newspaper. Sign me up!


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, https://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact